Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

BioNTech (BNTX): which funds own it

Health Care →Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow BNTX for free
Share

Sections with a free account

11 concentrated managers hold it (+2 vs last quarter) with a median weight of 0.5%.

Who owns BioNTech?

BioNTech trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): Athos KG, 40.2% (13G/A filed May 14, 2026), Prof. Ugur Sahin, M.D., 17.6% (13G/A filed May 13, 2025) and Ugur Sahin, 15.8% (13G/A filed May 15, 2026). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were FMR (7.6 million ADRs), Primecap Management (3.8 million ADRs) and Dodge & Cox (3.7 million ADRs).

Which institutions hold the most BioNTech shares?

Per Form 13F filings as of Jun 30, 2026, in ADRs:

  1. 1. FMR: 7.6 million ADRs
  2. 2. Primecap Management: 3.8 million ADRs
  3. 3. Dodge & Cox: 3.7 million ADRs
  4. 4. Von Storch Flossbach: 2.2 million ADRs
  5. 5. T. Rowe Price Investment Management: 2.1 million ADRs
  6. 6. BlackRock: 1.9 million ADRs
  7. 7. Temasek Holdings (Private): 1.5 million ADRs
  8. 8. BNP Paribas Financial Markets: 1.3 million ADRs
  9. 9. Logos Global Management: 1.0 million ADRs
  10. 10. GSK: 889,824 ADRs

Sources:13G/A by Athos KG (May 14, 2026) ↗13G/A by Prof. Ugur Sahin, M.D. (May 13, 2025) ↗13G/A by Ugur Sahin (May 15, 2026) ↗All of the company's proxy statements on EDGAR ↗

We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Concentrated managers
11
All 13F: 283
Consensus
17/100
across 11 concentrated managersRanks by accumulation, portfolio weight and number of managers; it does not say more are buying than selling.
Price at Jun 30, 2026 (per 13F)
$93.05
+4.7% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (9 → 11): 2 opened · 1 exited · 1 more with no comparable data = +2

“No comparable data”: managers whose previous-quarter portfolio we cannot compare (first 13F, or they did not file that quarter), plus spin-offs and corporate exits (mergers, delistings). They change the count without being a clean buy or sale. It is a net figure: “more” when more of them enter the count than leave it, “fewer” when it is the other way round. Here: 1 entered with no comparable quarter.

Net flow in the quarter: −$39.8M (−428 K shares) · bought $99.4M and sold $139MShares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

The set of concentrated managers changed between quarters: with the set as it was then, 7 held it last quarter (the chart point); with today's set, 9 (the base for the change).

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Other relevant holders

Filers with $100M or more in the stock that do not count as concentrated managers because of their type: they are left out of the counts, the consensus and the accumulation.

Largest holders of BNTX (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Insiders (Form 4)

Officers and directors who bought (6 m)
0
Amount (6 m)
$0
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

  • Ugur Sahin15.8%13G · amendmentfiling ↗Event: Mar 31, 2026 · filed: May 15, 2026
  • Athos KG40.2%13G · amendmentfiling ↗Event: Mar 31, 2026 · filed: May 14, 2026
  • Prof. Ugur Sahin, M.D.17.6%13G · amendmentfiling ↗Event: Mar 31, 2025 · filed: May 13, 2025

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow BNTX for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow BNTX